Trial reportAlcoholism, clinical and experimental research2009
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Trial report in Alcoholism, clinical and experimental research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01218958 (A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.CNS neuroscience & therapeutics · 2011Pooled it
- Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.The lancet. Psychiatry · 2021Trial
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.Contemporary clinical trials · 2014Trial
- Quality of life measures in treatment for active substance misuse: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Hazardous drinking and alcohol use disorders.Nature reviews. Disease primers · 2022Review
- Article
- Advances in the science and treatment of alcohol use disorder.Science advances · 2019Review
- Naltrexone: Not Just for Opioids Anymore.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2016Review
- The opioid receptors as targets for drug abuse medication.British journal of pharmacology · 2015Review
- Using the SF-6D to measure the impact of alcohol dependence on health-related quality of life.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Functional alterations in the dorsal raphe nucleus following acute and chronic ethanol exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Article
- Alcoholism risk reduction in France: a modernised approach related to alcohol misuse disorders.International journal of environmental research and public health · 2014Article
- Therapy for alcoholic liver disease.World journal of gastroenterology · 2014Review
- [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].Der Nervenarzt · 2013Review
- Long-acting Preparations in Substance Abuse Management: A Review and Update.Indian journal of psychological medicine · 2013Article
- Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.The American journal of managed care · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundExtended-release naltrexone (XR-NTX) is a once-a-month injectable formulation for the treatment of alcohol dependence previously shown to reduce drinking and heavy drinking relative to placebo (Garbutt et al., 2005). A 24-week, randomized, double-blind, placebo-controlled study established the efficacy and safety of XR-NTX in this patient population. In this report, the effect of XR-NTX on quality of life (QOL) was examined.
methodsAlcohol-dependent patients were randomly assigned to receive XR-NTX 380 mg (N = 205), XR-NTX 190 mg (N = 210), or placebo (N = 209), combined with a standardized psychosocial intervention. QOL was assessed using the Medical Outcomes Study 36-item short-form health survey, administered at baseline and at 4-week intervals during 24 weeks of treatment.
resultsCompared with U.S. population norms, patients showed initial impairment in the health-related QOL domains of mental health, social functioning, and problems with work or other daily activities due to emotional problems. Adherence to all 6 injections was 65% for XR-NTX 190 mg, 63% for XR-NTX 380 mg, and 64% for placebo. Generalized estimating equations analyses using an intention-to-treat sample revealed that XR-NTX 380 mg was associated with significantly greater improvements from baseline in mental health (p = 0.0496), social functioning (p = 0.010), general health (p = 0.048), and physical functioning (p = 0.028), compared with placebo. Linear regression analyses revealed that reductions from baseline in drinking (percentage of drinking days and percentage of heavy drinking days in the last 30 days) were significantly (p < 0.05) correlated with improvements in quality of life.
conclusionExtended-release naltrexone 380 mg in combination with psychosocial intervention was associated with improvements in QOL, specifically in the domains of mental health, social functioning, general health, and physical functioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.